8.75
price up icon4.04%   0.34
after-market After Hours: 8.66 -0.09 -1.03%
loading
Regenxbio Inc stock is traded at $8.75, with a volume of 890.91K. It is up +4.04% in the last 24 hours and up +6.58% over the past month. Regenxbio Inc is a biotechnology company. Its main activity is the development and commercialization of recombinant adeno associated virus gene therapy to correct an underlying genetic defect. The diseases that the Regenxbio platform targets are metabolic (homozygous familial hypercholesterolemia), neurodegenerative conditions (mucopolysaccharidosis), and retinal diseases (wet age-related macular degeneration, X-linked retinitis pigmentosa). The company derives the majority of its revenue from the United States.
See More
Previous Close:
$8.41
Open:
$8.7
24h Volume:
890.91K
Relative Volume:
0.92
Market Cap:
$440.90M
Revenue:
$89.04M
Net Income/Loss:
$-241.08M
P/E Ratio:
-1.6635
EPS:
-5.26
Net Cash Flow:
$-194.72M
1W Performance:
-3.74%
1M Performance:
+6.58%
6M Performance:
+10.76%
1Y Performance:
-38.77%
1-Day Range:
Value
$8.62
$9.32
1-Week Range:
Value
$8.27
$9.32
52-Week Range:
Value
$5.035
$15.02

Regenxbio Inc Stock (RGNX) Company Profile

Name
Name
Regenxbio Inc
Name
Phone
240-552-8181
Name
Address
9804 MEDICAL CENTER DRIVE, ROCKVILLE, MD
Name
Employee
353
Name
Twitter
@REGENXBIO
Name
Next Earnings Date
2025-03-04
Name
Latest SEC Filings
Name
RGNX's Discussions on Twitter

Compare RGNX with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
RGNX
Regenxbio Inc
8.75 442.92M 89.04M -241.08M -194.72M -5.26
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
469.16 118.34B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
554.58 60.31B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
339.80 42.35B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
598.89 36.43B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
299.94 31.87B 3.81B -644.79M -669.77M -6.24

Regenxbio Inc Stock (RGNX) Upgrades & Downgrades

Date Action Analyst Rating Change
Feb-11-25 Downgrade Goldman Buy → Neutral
Feb-07-25 Resumed Raymond James Outperform
Nov-15-24 Resumed Morgan Stanley Overweight
Oct-10-24 Resumed Raymond James Outperform
Jun-07-24 Initiated Goldman Buy
Mar-11-24 Initiated H.C. Wainwright Buy
Mar-08-24 Upgrade RBC Capital Mkts Sector Perform → Outperform
Mar-06-24 Upgrade Leerink Partners Market Perform → Outperform
Feb-21-24 Resumed Raymond James Outperform
Nov-01-23 Initiated Stifel Buy
Jun-02-23 Initiated Robert W. Baird Outperform
Jun-23-22 Initiated Berenberg Buy
Dec-15-21 Initiated Wedbush Neutral
Oct-19-21 Resumed Morgan Stanley Overweight
Jan-06-21 Upgrade Raymond James Outperform → Strong Buy
Dec-16-20 Initiated UBS Buy
Jun-25-20 Resumed BofA/Merrill Buy
May-13-20 Initiated RBC Capital Mkts Sector Perform
Aug-20-19 Upgrade SVB Leerink Underperform → Mkt Perform
Jun-18-19 Reiterated Chardan Capital Markets Buy
Jun-14-19 Resumed Raymond James Outperform
Jun-05-19 Reiterated Chardan Capital Markets Buy
Feb-25-19 Upgrade Evercore ISI In-line → Outperform
Feb-05-19 Upgrade Raymond James Outperform → Strong Buy
Dec-17-18 Reiterated Chardan Capital Markets Buy
Nov-08-18 Reiterated BofA/Merrill Neutral
Aug-08-18 Reiterated Chardan Capital Markets Buy
Jul-23-18 Downgrade BofA/Merrill Buy → Neutral
Jul-10-18 Reiterated Chardan Capital Markets Buy
May-09-18 Reiterated Barclays Overweight
Apr-09-18 Reiterated Chardan Capital Markets Buy
Mar-12-18 Downgrade Evercore ISI Outperform → In-line
Feb-13-18 Initiated Mizuho Neutral
Nov-09-17 Resumed Morgan Stanley Overweight
View All

Regenxbio Inc Stock (RGNX) Latest News

pulisher
12:15 PM

REGENXBIO Inc. Reaches Critical Trendline SupportLow Capital High Return Stock Plans Reviewed - metal.it

12:15 PM
pulisher
Jul 29, 2025

REGENXBIO Inc. Inches Above Key Support — Safe to HoldTarget Return Focused Trade Insights Shared - metal.it

Jul 29, 2025
pulisher
Jul 28, 2025

How many analysts rate REGENXBIO Inc. as a “Buy”AI Powered Tips For 2025 - jammulinksnews.com

Jul 28, 2025
pulisher
Jul 28, 2025

Duchenne Muscular Dystrophy Market to Witness Significant Expansion During the Forecast Period (2025–2034) Amidst Advances in Gene Therapy and Novel Drug Approvals | DelveInsight - GlobeNewswire Inc.

Jul 28, 2025
pulisher
Jul 28, 2025

What are the latest earnings results for REGENXBIO Inc.Get daily updates on promising stocks - jammulinksnews.com

Jul 28, 2025
pulisher
Jul 28, 2025

What is the dividend policy of REGENXBIO Inc. stockRobust investment performance - jammulinksnews.com

Jul 28, 2025
pulisher
Jul 28, 2025

What catalysts could drive REGENXBIO Inc. stock higher in 2025Maximize your portfolio’s earning power - jammulinksnews.com

Jul 28, 2025
pulisher
Jul 27, 2025

What makes REGENXBIO Inc. stock price move sharplyBuild a portfolio that stands the test of time - jammulinksnews.com

Jul 27, 2025
pulisher
Jul 25, 2025

What drives REGENXBIO Inc. stock priceJaw-dropping returns - PrintWeekIndia

Jul 25, 2025
pulisher
Jul 24, 2025

What institutions are buying REGENXBIO Inc. stock nowTriple returns potential - jammulinksnews.com

Jul 24, 2025
pulisher
Jul 24, 2025

REGENXBIO Inc. (RGNX): A Bull Case Theory - Insider Monkey

Jul 24, 2025
pulisher
Jul 23, 2025

What analysts say about REGENXBIO Inc. stockStrong return on investment - Autocar Professional

Jul 23, 2025
pulisher
Jul 23, 2025

The Duchenne Gene Therapies Lining Up To Take Elevidys’ Place - insights.citeline.com

Jul 23, 2025
pulisher
Jul 22, 2025

REGENXBIO Inc. Stock Analysis and ForecastExplosive trading opportunities - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 22, 2025

Is REGENXBIO Inc. a good long term investmentConsistently outstanding ROI - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 18, 2025

REGENXBIO Inc. (NASDAQ:RGNX) is largely controlled by institutional shareholders who own 67% of the company - Yahoo Finance

Jul 18, 2025
pulisher
Jul 18, 2025

(RGNX) Technical Pivots with Risk Controls - news.stocktradersdaily.com

Jul 18, 2025
pulisher
Jul 11, 2025

REGENXBIO announces royalty monetization agreement for up to $250M - MSN

Jul 11, 2025
pulisher
Jul 10, 2025

REGENXBIO’s gene therapy with CT domain shows improved muscle function in study By Investing.com - Investing.com South Africa

Jul 10, 2025
pulisher
Jul 10, 2025

REGENXBIO’s gene therapy with CT domain shows improved muscle function in study - Investing.com

Jul 10, 2025
pulisher
Jul 10, 2025

REGENXBIO Announces Publication of Preclinical Results Demonstrating Functional Benefits of Novel Microdystrophin Construct in RGX-202 Investigational Gene Therapy for Duchenne Muscular Dystrophy - WV News

Jul 10, 2025
pulisher
Jul 09, 2025

Diabetic Retinopathy Pipeline 2025: MOA and ROA Insights, Clinical Trials Status, and Key Companies Involved by DelveInsight | | Kodiak Sciences, Novartis, Regenxbio Inc., OcuTerra Therapeutics - Barchart.com

Jul 09, 2025
pulisher
Jul 08, 2025

RBC Capital Remains a Buy on RegenXBio (RGNX) - The Globe and Mail

Jul 08, 2025
pulisher
Jul 08, 2025

RBC Capital Maintains Regenxbio(RGNX.US) With Buy Rating, Cuts Target Price to $21 - 富途牛牛

Jul 08, 2025
pulisher
Jun 16, 2025

Regenxbio (RGNX) Maintains Strong Outlook Amid Competitor Safety Concerns | RGNX Stock News - GuruFocus

Jun 16, 2025
pulisher
Jun 14, 2025

REGENXBIO (RGNX) Prepares for Potential $4M Warrant Cash Influx - GuruFocus

Jun 14, 2025
pulisher
Jun 13, 2025

Regenxbio (RGNX) Proposes Sale of Over 268,000 Shares | RGNX Stock News - GuruFocus

Jun 13, 2025
pulisher
Jun 09, 2025

Regenxbio (RGNX) Maintains Buy Rating with $52 Price Target | RGNX Stock News - GuruFocus

Jun 09, 2025
pulisher
Jun 09, 2025

A Glimpse Into The Expert Outlook On Regenxbio Through 8 Analysts - Benzinga

Jun 09, 2025
pulisher
Jun 09, 2025

Promising RGX-202 Trial Results Justify Buy Rating for RegenXBio Amid Market Skepticism - TipRanks

Jun 09, 2025
pulisher
Jun 07, 2025

REGENXBIO updates Phase 1/2 data for Duchenne candidate - MSN

Jun 07, 2025
pulisher
Jun 06, 2025

Regenxbio's RGX-121 Could Become The New Standard Of Care In Hunter Syndrome - Seeking Alpha

Jun 06, 2025
pulisher
Jun 06, 2025

H.C. WAINWRIGHT MAINTAINS BUY RATING ON REGENXBIO STOCK AFTER POSITIVE TRIAL DATA - Investing.com Nigeria

Jun 06, 2025
pulisher
Jun 06, 2025

Duchenne gene therapy interim trial outcomes "striking" - MarketScreener

Jun 06, 2025

Regenxbio Inc Stock (RGNX) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading

Regenxbio Inc Stock (RGNX) Insider Trading

Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total
Mills Kenneth T.
Director
May 12 '25
Sale
7.91
20,602
163,046
475,103
$77.55
price up icon 0.23%
$37.12
price down icon 0.40%
$105.18
price up icon 0.17%
$26.66
price down icon 0.30%
$110.05
price down icon 1.28%
biotechnology ONC
$299.94
price down icon 1.90%
Cap:     |  Volume (24h):